Eli Lilly Q1 top line up 8%; earnings down 125%; EPS guidance lowered

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (NYSE:LLY) Q1 results ($M): Total Revenues: 5,228.3 (+7.5%); Animal Health: 769.4 (+2.0%).

Net Income: (110.8) (-125.2%); Non-GAAP Net Income: 1,039.3 (+17.8%); EPS: (-0.10) (-124.4%); Non-GAAP EPS: 0.98 (+18.1%).

Key Product Sales: Humalog: 708.4 (+16.8%); Cialis: 533.6 (-7.5%); Alimta: 489.9 (-13.2%); Forteo: 347.5 (+9.1%); Humulin: 314.5 (-11.8%); Trulicity: 372.9 (+159.7%); Cyramza: 171.2 (+30.7%).

New Product Sales: Taltz: 96.6; Jardiance: 74.0: Basaglar: 46.0; Lartruvo: 42.1; Portrazza: 3.6.

2017 Guidance: Total Revenues: $21.8B - 22.3B (unch); EPS: $2.60 - 2.70 from $2.69 - 2.79; Non-GAAP EPS: $4.05 - 4.15 (unch).